Alembic Pharmaceuticals Ltd.

SECTOR: Pharmaceuticals & Drugs

837.8
₹ -15.05 (-1.76%)
Today's High: 870 Today's Low : 829.65
52 Week High: 913.00 52 Week Low : 435.10
 FinStar
FinStar Indicates the overall health and quality of a stock based on Finology Research.
Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.

 Company Essentials

Market Cap

15793.86327492 Cr.

P/E

16.29

P/B

4.72

Face Value

₹2

Div. Yield

1.11%

Book Value (TTM)

177.4929

Enterprise Value

16702.34327492 Cr.

CASH

150.8 Cr.

DEBT

1059.28 Cr.

Promoter Holding

72.97%

EPS (TTM)

51.4227

Sales Growth

24.30 %

ROE

24.91 %

ROCE

23.66 %

Profit Growth

44.84 %

No. of Shares

18.8515914 Cr.

Add your own Ratio
* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

 Price Chart 1w1m3m6m1Yr3Yr5Yr

* Prices are based on daily market changes.

 Valuation Chart 1w1m3m6m1Yr3Yr5Yr

* The chart is based on the standalone earnings of the company.

 Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Sales Growth

1 Year24.28%
3 Year6.75%
5 Year14.7%

 Profit Growth

1 Year44.79%
3 Year-4.39%
5 Year20.72%

 ROE

1 Year24.91%
3 Year23.68%
5 Year33.86%

 ROCE

1 Year23.66%
3 Year26.34%
5 Year38.44%

 Debt Equity

0.39

 Price to Cash Flow

19.53

  Interest Cover Ratio

52.42

 CFO/PAT (5 Yr Avg.)

0.929054517000846

 Share Holding Pattern

 Promoter Pledging %

Date Promoter % Pledge %
Mar 2020 72.97 0
Dec 2019 72.97 0
Sep 2019 72.97 0
Jun 2019 72.97 0
Mar 2019 72.97 0
* Figures given above are % of equity capital

 Strengths

  • Company has been maintaining healthy ROE of 23.68% over the past 3 years.
  • Company has been maintaining healthy ROCE of 26.3433333333333% over the past 3 years.
  • Company has a healthy Interest coverage ratio of 52.42.
  • The Company has been maintaining an effective average operating margins of 23.274% in the last 5 years.
  • Company’s PEG ratio is 0.363345575520457.
  • The company has an efficient Cash Conversion Cycle of 57.57 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.32373158756137.
  • The company has a high promoter holding of 72.97%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 18.5019533576699.

 Limitations

  • The company has shown a poor profit growth of -4.38603135018493% for the Past 3 years.
  • The company has shown a poor revenue growth of 6.74633325041496% for the Past 3 years.

 Quarterly Result (All Figures are in Crores.)

Particulars Mar 2019 Jun 2019 Sep 2019 Dec 2019 Mar 2020
Net Sales 848.7 896.74 1134.9 1052.36 1048.56
Other Income 0.89 3.18 0.28 0.29 131.01
Total Expenditure 695.68 671.96 774.17 731.24 752.29
Operating Profit 153.91 227.96 361.01 321.41 427.28
Interest 4.34 4.66 6.63 6.93 6.97
Depreciation 27.49 32.5 32.51 34.31 36.35
Exceptional Items 0 0 0 0 -10
Profit Before Tax 122.08 190.8 321.87 280.17 373.96
Tax 14.42 35.58 53.18 48.97 59.66
Profit After Tax 107.66 155.22 268.69 231.2 314.3

 Profit & Loss (All Figures are in Crores except Adjusted EPS in Rs.)

Particulars Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019
Net Sales 2019 3009 2986 2945 3660
Other Income 5.61 42 3 41 26
Total Expenditure 1614.19 2061 2353 2346 2801
Operating Profit 410.41 990 636 639 885
Interest 3.14 4 3 2 15
Depreciation 44.41 72 83 102 106
Exceptional Items 0 0 0 0 0
Profit Before Tax 362.86 914 550 535 765
Tax 76.25 215 119 113 153
Net Profit 286.61 699 431 422 611
Adjusted EPS 15 37 23 22 32

 Balance Sheet (All Figures are in Crores.)

Particulars Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019
Equity and Liabilities
Share Capital 37.7 37.7 37.7 37.7 37.7
Total Reserves 795.86 1493.03 1829.62 2156.93 2674.71
Borrowings 18.8 0 0 500 499.3
Other N/C liabilities 53.64 83.91 101 85.07 96.6
Current liabilities 605.15 567.08 540.81 898.19 1240.72
Total Liabilities 1511.16 2181.72 2509.13 3677.89 4549.03
Assets
Net Block 488.68 697.25 799.01 918.3 1077.09
Capital WIP 83.14 92.34 347.75 740.64 1106.89
Investments 33.33 37.46 103.04 298.89 514.74
Loans & Advances 65.03 29.96 36.53 44.37 14.31
Other N/C Assets 0 0 0 0 0
Current Assets 840.98 1324.71 1222.8 1675.69 1836
Total Assets 1511.16 2181.72 2509.13 3677.89 4549.03
* Other Non-current Liabilities include Net deferred Liabilities

 Cash Flows (All Figures are in Crores.)

Particulars Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019
Profit Before Tax 362.86 914.01 549.71 535.22 764.63
Adjustment 34.84 72.96 84.88 81.9 94.49
Working Capital Changes -148.53 56.63 -189.44 -188.46 107.37
Tax Paid -69.1 -196.08 -117.99 -124.11 -157.69
Operating Cash Flow 180.08 847.52 327.16 304.55 808.8
Investing Cash Flow -198.51 -291.91 -510.97 -793.58 -753.59
Financing Cash Flow 17.5 -276.05 -96.06 497.8 79.67
Net Cash Flow -0.93 279.56 -279.87 8.77 134.88

 Corporate Actions

 Ratings & Research Reports

 Company Presentations

 Alembic Pharma Stock Price Analysis and Quick Research Report

Is Alembic Pharma an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Alembic Pharma and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 808.8 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Alembic Pharma has a Debt to Equity ratio of 0.390530930058509 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Alembic Pharma , the EPS growth was 44.84 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Alembic Pharma has OPM of 23.4761370062864 % which is a good sign for profitability.
     
  • ROE: Alembic Pharma have a healthy ROE of 24.9115556425055 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
X